Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (2.849)

91

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

in: Cancer Nanotechnology | 2024

von Paige Baldwin | Shicheng Yang | Adrienne Orriols | +3

92

Study of PARP inhibitors for breast cancer based on enhanced multiple kernel function SVR with PSO

in: Frontiers in Pharmacology | 2024

von Haohan Xue | Ruixuan Zhang | Xudong Yan | +2

93

Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review

in: International Journal of Molecular Sciences | 2024

von Kiyotaka Watanabe | Nobuhiko Seki

94

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

in: Biomolecules & Biomedicine | 2024

von Lama Abujamous | Abderrezzaq Soltani | Hamda Al-Thawadi | +1

95

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

in: Frontiers in Pharmacology | 2024

von Yan Wei | Li He | Tao Liu | +6

96

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

in: International Journal of Molecular Sciences | 2024

von Morgan Bailey | Susan Morand | Rachel Royfman | +6

97

Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer : a cross-sectional survey

enthalten in: Journal of gynecologic oncology | 2024

von Kim, J. | Lee, Y. | Kim, D. | +5

98

PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis

enthalten in: Canadian journal of physiology and pharmacology | 2024

von Zaza, M. | Rashed, M. | Elrefaey, H. | +3

99

Platinum-based chemotherapy in metastatic prostate cancer : what possibilities?

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Catalano, M. | Lapucci, A. | Nobili, S. | +7

100

Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer

enthalten in: Current cancer drug targets | 2024

von Guo, Y. | Chen, X. | Tang, X. | +3